Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa
Abstract Although viral suppression is attained for most adults living with diagnosed HIV in East, Central, Southern and West Africa (ECSWA), challenges remain with sustained adherence to daily oral pill taking for some in the population. Here, we evaluate the potential effectiveness and cost-effect...
Saved in:
| Main Authors: | Andrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, Kenly Sikwese, Cissy Kityo, Charles Flexner, Marco Vitoria, Nathan Ford, Meg Doherty, Zack Panos, David Ripin, Matthew Hickey, Diane Havlir, Monica Gandhi, Michael Reid, Paul Revill |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60752-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenacapavir’s success: Revitalizing antiviral drug discovery
by: Daniel Miranda, et al.
Published: (2025-12-01) -
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
by: Derek Hansen, et al.
Published: (2025-05-01) -
Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
by: Ferdinand Bigirimana, et al.
Published: (2023-01-01) -
The primary mechanism for highly potent inhibition of HIV-1 maturation by lenacapavir.
by: Szu-Wei Huang, et al.
Published: (2025-01-01) -
Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.
by: Andrew N Phillips, et al.
Published: (2016-01-01)